Tirzepatide is a new once-weekly injectable medication that acts as a dual GIP and GLP-1 receptor agonist.
Many patients feel cautious about new medications. This concern is especially common when it comes to tirzepatide (Mounjaro), a drug used for weight loss and blood sugar control in type 2 diabetes. Let’s take a closer look at whether it is truly “untested.”
In fact, tirzepatide has undergone large, multi-stage international clinical trials — the SURPASS and SURMOUNT programs — involving thousands of patients with various conditions. These studies lasted up to 72 weeks (over a year) and demonstrated that tirzepatide not only effectively reduces body weight but also helps stabilize blood glucose levels.
The medication is already approved for use in the United States and other countries. This means it has passed all the necessary stages of evaluation for safety and efficacy. Moreover, its use continues to be carefully monitored — like any modern medication, it remains under ongoing surveillance by specialists.
Yes, tirzepatide is a modern therapy. But calling it “untested” is inaccurate. It is currently one of the most well-studied and promising medications in its field. It works by targeting two hormonal pathways that regulate appetite and blood sugar, which explains its higher effectiveness compared to many other treatments.
It is important to understand that in medicine we evaluate not only “novelty,” but also the balance between benefits and potential risks. By these criteria, tirzepatide demonstrates an excellent safety profile, especially when properly dosed and monitored by a physician.
If you have any concerns, be sure to discuss them with your doctor. Treatment should always be individualized, taking into account your goals and overall health.